Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Genzyme reports Phase III data showing Campath is superior to Chlorambucil as a first-line therapy in B-CLL

BTG : 16 April, 2007  (Company News)
BTG plc, the medical innovations company, notes that its licensee Genzyme Corporation has published positive results from a Phase III study comparing Campath with Chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukaemia. An extract from the announcement follows.
BTG plc, the medical innovations company, notes that its licensee Genzyme Corporation has published positive results from a Phase III study comparing Campath with Chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukaemia. An extract from the announcement follows.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo